also performed on all participants. Like the patients, controls also underwent physical and neuropsychiatric examination, neuropsychological tests, and neuroimaging screening. All the tests in patients and controls were part of routine screenings or check-ups that took place prior to the start of the study. Table 1 shows the demographic and clinical (i.e., cognitive scores) characteristics of the participants. None of them was taking antipsychotics, sedatives, antidepressants or cholinesterase inhibitors at the time of recruitment. Prior to the beginning of the study, all the procedures were explained in detail to the participants by qualified neuropsychiatrists, including the authors of this study (RC and LC). Subsequently, written informed consent was obtained from all capable participants. In those considered to have reduced capacity to understand the informed consent document due to their cognitive deficits, a legal representative or caregiver consented on their behalf. This study and the consent procedures were approved by the institutional review board of the EuroEspes Medical Center, in line with the ethical code of the World Medical Association (Declaration of Helsinki).
